Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
Summit Therapeutics (SMMT) reported its financial results for the fourth quarter and year ending December 31, 2022. The company is progressing with its Collaboration and License Agreement with Akeso, acquiring rights to ivonescimab, a bispecific antibody for cancer treatment, for an upfront payment of $500 million. Key financials include a net loss of $78.8 million for the year, a significant decrease from $88.6 million in 2021. Summit raised $500 million in a Rights Offering to fund ongoing operations, with sufficient capital expected to cover expenses into late 2024. An earnings call is scheduled for March 9, 2023.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on prostate cancer therapies, announced its presentation at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 11:20 a.m. Eastern Time. The event will feature David R. Parkinson, President and CEO, along with COO Peter Virsik and CFO David S. Wood, who will also participate in one-on-one meetings. Investors can access a live webcast through ESSA's website, with an archived version available for 90 days post-event. ESSA aims to develop novel therapies to improve prostate cancer treatment outcomes.
On February 13, 2023, ESSA Pharma Inc. (NASDAQ: EPIX) announced that further analyses from two Phase 1 studies of EPI-7386 will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium from February 16-19 in San Francisco. EPI-7386 is a novel androgen receptor inhibitor showing promising initial anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC). Early data indicates that the combination with enzalutamide has led to sustained declines in prostate-specific antigen (PSA) levels in patients. ESSA is preparing to enroll 120 patients in a Phase 2 study across the U.S., Canada, and Australia.
ESSA Pharma Inc. (NASDAQ: EPIX) reported a comprehensive loss of $6.7 million for the first quarter ended December 31, 2022, an improvement from $9.1 million in the same period of 2021. The company continues to advance its clinical studies of EPI-7386, a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), with completion of the Phase 1 combination study with enzalutamide expected in 1H2023, followed by a Phase 2 study. As of December 31, 2022, ESSA maintained a solid cash position of $163.1 million, sufficient to fund operations through 2025.
ESSA Pharma Inc. (NASDAQ: EPIX) announced its participation in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference on February 9, 2023, at 9:00 a.m. Eastern Time in New York City. Key executives, including President and CEO David R. Parkinson, will also hold one-on-one meetings. A live webcast of the presentation will be available on ESSA's website, with an archived replay accessible for 30 days after the event. ESSA focuses on developing novel therapies for prostate cancer, aiming to provide innovative treatment solutions for patients.
ESSA Pharma Inc. (EPIX) reported key corporate updates and financial results for the fiscal year ending September 30, 2022. The company achieved significant milestones with its lead candidate EPI-7386, showing initial anti-tumor activity in clinical trials for metastatic castration-resistant prostate cancer (mCRPC). ESSA recorded a net loss of $35.1 million, compared to $36.8 million in 2021, while R&D expenses remained consistent at $24.4 million. As of September 30, 2022, the company had a strong cash position of $167.2 million, expected to fund operations through 2025.
ESSA Pharma (NASDAQ: EPIX) announced its participation in two investor conferences, aimed at discussing its innovative prostate cancer therapies. The events include:
- Jefferies London Healthcare Conference: November 17, 2022, at 3:15 p.m. GMT.
- Piper Sandler 34th Annual Healthcare Conference: November 29, 2022, at 4:30 p.m. ET.
David R. Parkinson, CEO, along with other executives, will host one-on-one meetings. A live webcast of the Jefferies chat will be available on ESSA's website, archived for 90 days.
ESSA Pharma Inc. (NASDAQ: EPIX) reported on October 31, 2022, that Janssen Research and Development has suspended enrollment in the Phase 1 clinical study of EPI-7386 in advanced prostate cancer due to recruitment challenges. Despite this setback, three patients treated showed favorable safety and initial clinical activity, with two achieving a 90% reduction in PSA levels within 12 weeks. ESSA plans to continue discussions with Janssen for a potential combination study and retains global rights to EPI-7386, which has received FDA Fast Track designation.
ESSA Pharma Inc. (NASDAQ: EPIX) presented preclinical data for its first generation androgen receptor (AR) degrader, EPI-8207, at the 34th EORTC-NCI-AACR Annual Symposium in Barcelona. The data shows EPI-8207 effectively degrades AR, including splice variants and mutants associated with castration-resistant prostate cancer. This research highlights the potential of ANITAC in targeting AR signaling, a key driver in prostate cancer progression. The study indicates EPI-8207's high potency in inhibiting AR-dependent transcription, positioning ESSA for advancements in prostate cancer therapy.
ESSA Pharma Inc. (NASDAQ: EPIX) announced promising results from a Phase 1/2 trial of its lead candidate, EPI-7386, in combination with enzalutamide for treating metastatic castration-resistant prostate cancer. The study showed that the combination therapy was safe with no dose-limiting toxicities, and 5 out of 6 patients experienced significant prostate-specific antigen (PSA) reductions. The pharmacokinetics indicated minimal impacts on enzalutamide exposure. ESSA is currently enrolling a third dose escalation cohort to optimize the therapeutic dose.
